Table 4.
Distribution of C4 polymorphisms in Graves' disease patients with or without Graves' ophthalmopathy
| Variations | GO |
P value, individuala [OR (95%CI), individual]c |
P value b | OR (95%CI)d | |
|---|---|---|---|---|---|
| No, N (%) | Yes, N (%) | ||||
| C4 CNV | |||||
| 4 | 196 (49.4) | 118 (52.0) | 0.561 | 0.396 | (Reference) |
| < 4 | 92 (23.2) | 42 (18.5) | 0.188 | 0.978(0.614-1.558) | |
| > 4 | 109 (27.5) | 67 (29.5) | 0.581 | 1.029(0.687-1.540) | |
| C4A CNV | |||||
| 2 | 238 (39.9) | 157 (69.2) | 0.025 [1.436 (0.994-2.075)] | 0.014 | (Reference) |
| < 2 | 61 (15.4) | 18 (7.9) | 0.008 [0.590 (0.328-1.059)] | 0.549 (0.303-0.998) | |
| > 2 | 98 (24.7) | 52 (22.9) | 0.628 | 0.772 (0.509-1.169) | |
| C4B CNV | |||||
| 2 | 229 (57.7) | 148 (65.2) | 0.074 | 0.186 | (Reference) |
| < 2 | 97 (24.4) | 46 (20.3) | 0.276 | 0.806 (0.520-1.249) | |
| > 2 | 71 (17.9) | 33 (14.5) | 0.316 | 0.697 (0.430-1.132) | |
| C4 polymorphisms | |||||
| A2B2 | 149 (37.5) | 105 (46.3) | 0.035 [1.283 (0.900-1.828)] | 0.005 | (Reference) |
| A2B1 | 53 (13.4) | 25 (11.0) | 0.451 | 0.796 (0.449-1.411) | |
| A3B2 | 37 (9.3) | 27 (11.9) | 0.338 | 1.067 (0.596-1.912) | |
| A2B3 | 29 (7.3) | 15 (6.6) | 0.871 | 0.734 (0.366-1.476) | |
| A3B1 | 25 (6.3) | 7 (3.1) | 0.091 | 0.374 (0.146-0.960) | |
| A1B2 | 28 (7.1) | 6 (2.6) | 0.026 [0.451(0.176-1.160)] | 0.374 (0.153-1.056) | |
| Other | 65 (16.4) | 40 (17.6) | 0.894 (0.549-1.455) | ||
Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
aIndividual C4 CNVs and polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 2 × 2 contingency tables.
b CNV of C4, C4A and C4B between GD patients with or without GO were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
cORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.
dORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.